BioSim™ - ELISA Kits for Biosimilar Antibodies
Therapeutic Monoclonal Antibodies:
Monoclonal Antibodies (mAbs) represent one of the most important classes of biotherapeutic agents. They are used in the treatment of many diseases, including cancer, autoimmune diseases, cardiovascular and hematologic diseases. Therapeutic antibodies are specific to tumor cell-surface proteins and have tumor specificity and the potency is not achievable with traditional drugs. Several mechanisms of tumor cell killing by antibodies (mAbs) can be summarized as direct action through receptor blockade or induction of apoptosis immune-mediated cell killing by complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) or by regulation of T cell function.
Biosimilar Antibodies:
Biosimilars Antibodies are antibodies that are highly similar to existing biological products with no differences in terms of safety and efficacy. With the ever-increasing cost of health care and the economic pressure to reduce healthcare expenses, FDA approved biosimilars can be a promising alternative in reducing cost for the medication cost and increasing patient’s access to treatments. Research grade Biosimilars are cost-effective research tools that can be used as controls for preclinical lead identification and potency assays for the development of novel therapeutics.
BioSim™ ELISA Kits for Biosimilar Antibodies:
BioVision’s BioSim™ ELISA kits are designed to detect and quantify the Biosimilar Antibodies and anti-drug antibody in human serum and plasma. These ELISA kits can be used to measure the free-form of Biosimilar Antibodies in patients or study the dose-dependent pharmacokinetics in animals as well as to identify biomarkers for (non-) response and risk factors for adverse drug reactions.
Features & Benefits
• Ready to use
• Rapid and Simple: No expensive equipment or special handling/disposal required
• Accurate: Reproducible results with low intra & inter assay variability
• Highly Sensitive and Specific: No significant cross-reactivity or interference with other proteins present in native human serum or other therapeutic immunoglobulins.
